StockData

Elanco Animal Health vs Perrigo

ELAN and PRGO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ELAN and PRGO compare

Elanco Animal Health is the larger company, worth 5.9 times as much as Perrigo ($13.2B against $2.2B).

Elanco Animal Health grew revenue faster over the last twelve months (12.0% versus −4.2% for Perrigo).

Elanco Animal Health keeps more of each dollar of sales as profit, with a net margin of −4.0% compared with −41.9% at Perrigo.

Perrigo pays a dividend yielding 5.4%; Elanco Animal Health does not pay one.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricELANPRGO
Size and price
Market cap$13.2B$2.2B
Share price$26.41$16.18
Change, 1 year20.1%15.8%
Change, 5 years−12.6%−57.2%
Beta (5Y)0.091.98
Employees9,4008,100
StockData Score
Total score99
Valuation score12 (better)
Growth score3 (better)0
Performance score3 (better)2
Health score2 (better)1
Dividend score04 (better)
Valuation
P/S2.6×0.5× (better)
P/B2.0×0.9× (better)
EV/EBITDA31.5×–
P/FCF34.8×18.8× (better)
FCF yield2.9%5.3% (better)
Fair value$11.30$17.35
Margin of safety−134%6.7% (better)
Growth
Revenue growth (TTM)12.0% (better)−4.2%
Revenue growth, 5Y average7.6% (better)0.79%
Net income growth (TTM)−146%–
EPS growth (TTM)−149%–
Profitability
Gross margin55.4% (better)33.3%
Operating margin–−37.7%
Net margin−4.0% (better)−41.9%
FCF margin7.5% (better)2.9%
Return on equity−3.0% (better)−49.6%
Return on invested capital–−18.9%
Financial health
Debt / equity0.59 (better)1.31
Net debt / EBITDA6.43–
Current ratio2.052.32 (better)
Altman Z-score1.46 (better)−0.38
Piotroski F-score6 (better)4
Dividends and buybacks
Dividend yield–5.4%
Years of dividend growth–11
Dividend growth, 5Y average–5.2%
Shareholder yield0.00%5.4% (better)
Ownership
Held by institutions113%116%
Held by insiders1.1%0.36%
Insider net buying, 12 months$2.5M (better)$0
Short interest, % of float6.7%17.8%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.